As we go through life, we face many changes. Some are happy, like the birth of a child or the accomplishment of a goal, while others, like illness and physical limitations, are harder to embrace. Such experiences are on my mind because I’m preparing for my yearly wellness check. In…
Read more
Increases in new onset or recurring depression were seen among older Canadian adults with chronic obstructive pulmonary disease (COPD) during the early stages of the COVID-19 pandemic, a study shows. One in six patients without a history of depression before the pandemic developed it early on in it. For…
Several months ago, I was selected by the pharmaceutical company Sanofi to be screened for a clinical trial called AERIFY-1. The study, which is being conducted by the global research company Care Access, aims to assess the efficacy, safety, and tolerability of the investigational therapy itepekimab in…
The U.S. Food and Drug Administration (FDA) has agreed to review Verona Pharma’s application seeking approval of inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). FDA’s review team now has up to 10 months to examine all data filed with the new drug…
As columnist Caroline Gainer prepares to present about COPD at the GOLD conference on Nov. 13, she must overcome several sources of anxiety.
In this podcast series, pulmonary specialist Dr. Noah Greenspan discusses topics related to pulmonary diseases, including COPD.
COPD is a chronic inflammatory disease of the lungs, in which the airways become blocked, causing cough with mucus, wheezing, and shortness of breath.
The causes of COPD are not fully understood. However, long-term exposure to lung irritants is known to damage the lungs and the airways.
Some people may also experience exacerbations, or episodes of sudden disease worsening, that may persist for several days.
Get regular updates to your inbox.